General Information
Revision date
2020-01-14
Product name
Insulin Aspart Injection (100 Units/mL)
Chemical name
Mixture
1.2.2. Uses advised against
None known
supplier name
Novo Nordisk Inc
Manufacturer Name
Novo Nordisk Inc
Icons in SDS
Company Information
company name
Novo Nordisk Inc
GHS Information
Signal word
Not required
Section 2
SECTION 2: Hazards identification
WHMIS 2015 Classification of the chemical
Signal word
Not required Hazard statement(s) Not required
Precautionary statements
Not required
Other hazards which do not result in classification
May cause mild skin irritation. May result in severe hypoglycemia This document has been prepared in accordance with standards for workplace safety, which require the inclusion of all known hazards of the product or its ingredients regardless of the potential risk. Your needs may vary depending upon the potential for exposure in your workplace. The precautionary statements, warnings and hazards included herein may not apply in all cases, such as when the product or device is in its final form and being used to treat the approved medical condition(s) while under the care of a licensed medical professional and in accordance with the FDA-approved Prescribing Information. Refer to FDA-approved Prescribing Information for final marketed products containing semaglutide tablets with regard to special storage, handling and administration requirements in the clinical setting.
2.1 Classification of the substance or mixture
This material, Insulin Aspart Injection 100 units/mL is not considered hazardous by OSHA Hazcom 2012 or WHMIS
